Boston Scientific's First 2026 Acquisition: eCoin from Valencia Technologies to Expand Urology Portfolio and Counter Medtronic

Jan 12, 2026 22:10 CST Updated 22:10

Valencia Technologies

Developer of Implantable Neurostimulation Devices

Medtronic

Medical Device Manufacturer

Axonics

Developer of Novel Implantable Neuromodulation Technologies

Boston Scientific Announces Collaboration withValencia TechnologiesA final acquisition agreement has been reached.Valencia TechnologiesCore ProducteCoinIs the first FDA-approvedImplantation into the tibiaNeurostimulator (Approved in 2022, three years earlier than Medtronic).

Executive Evaluation

"The inclusion of eCoin in the Boston Scientific portfolio will drive our expansion into the implantable tibial nerve stimulation space, a new high-growth avenue for the urology business. ITNS technology complements our existing pelvic health product line, and we look forward to offering more comprehensive treatment solutions for patients across the entire care continuum."

---Meghan Scanlon Senior Vice President and President of Boston Scientific's Urology Division

In the United States, nearly 30 million adults aged 40 and above are affected by symptoms of overactive bladder. This condition can significantly impact quality of life, mental health, sleep, work productivity, and social activities.

InImplantation into the tibiaBefore the neurostimulator was marketed, patients mainly received treatment through sacral nerve stimulators.However, after sacral nerve stimulation treatment, patients often face many complications and a high proportion of secondary surgeries. Additionally, the complexity, invasiveness, cost, and other factors associated with sacral nerve stimulation therapy result in very few patients willing to accept it. In the United States, only 150,000 patients have received neurostimulation treatment, accounting for only O1% of AB patients. This also leads to a large number ofPatients with overactive bladder symptoms have not received effective treatment, leading to a poor quality of life and occasional urinary leakage.

As the leader in the field of urology, Boston Scientific has been committed to solving the issue of urinary incontinence. Therefore, Boston Scientific invested in 2024.$3.7 Billion AcquisitionAxonics. In order to be able to obtainAxonics, in addition to spending $3.7 billion, Boston Scientific also reached a settlement with Medtronic (Boston Scientific paid a large sum to Medtronic to resolve the dispute between Medtronic andAxonicsInfringement Litigation）。

The urinary incontinence market is changing rapidly,TibiaNeurostimulators are increasingly favored by patients due to fewer complications. Moreover, Medtronic'sTibiaThe neurostimulator Altaviva also received FDA approval last year. This has put Boston Scientific in a passive position in the urinary incontinence field. Therefore, Boston Scientific is also in urgent need of supplementation.TibiaNeurostimulator,Valencia TechnologiesUndoubtedly the best target.Valencia TechnologiesProductseCoinIt has been on the market for many years and has been clinically proven to be safe and effective (In the eCoin pivotal clinical trial, 68% of patients achieved a reduction of at least 50% in the number of urge incontinence episodes.）。

Once Boston Scientific completes the acquisition, it will be able toeCoinIntegrated sales with the Axonics series of products to quickly capture the market.

eCoin

eCoinIt is a revolutionary leadlessTibial nerve stimulator, used to address issues caused byOveractive Bladder（OAB）Urinary urgency and incontinence issues triggered by.

eCoinCompare to one Chinese Yuan (Diameter: 25mm) Small, which can be completed in an outpatient setting (only local anesthesia is required).eCoinThe internal structure is also very "simple," including a battery and a chip. Once implanted, it automatically provides intermittent stimulation to the tibial nerve, which helps alleviate UUI symptoms.

Compared with traditionalSacral Nerve StimulatorIn comparison,eCoinThe surgery becomes simple and reliable. Due toeCoinLeadless design, addressing traditional product issuesIt is necessary to precisely thread the fragile wire through the epidermis to reach the treatment area, connecting with the nerve.After对接.RetrieveAndeCoinThe surgery is much simpler, requiring onlyeCoinImplanted above the tibial nerve at the ankle joint, its broad dome-shaped stimulation field provides regular stimulation to the nerve to stabilize the bladder and relieve bladder leakage. Meanwhile,eCoinAfter implantation, it is difficult to detect, ensuring patient privacy.

eCoin Demonstration

Valencia Technologies

Valencia Technologiesis a company located in Valencia, California.Neuromodulation Company, Dedicated to Improving the Standard of Care for Bladder Dysfunction.Designed and manufactured the eCoin® device for the treatment of urgency urinary incontinence (UUI).